Literature DB >> 24685972

Antidepressants and sexual dysfunction: mechanisms and clinical implications.

Anita H Clayton1, Harry A Croft, Lata Handiwala.   

Abstract

INTRODUCTION: Depression is one of the more prevalent mental disorders in the United States, with estimates as high as 6.7% of Americans affected annually. Consequently, antidepressant use in the United States is also widespread. Both depression and its treatments are associated with sexual dysfunction (SD) in men and women, including orgasm and arousal problems, hypoactive sexual desire, premature ejaculation, erectile difficulties, and dyspareunia. Sexual dysfunction is frequently cited as a reason for nonadherence or discontinuation of treatment for depression. AIM: The objective of our review is to aid physicians, including primary care physicians, psychiatrists, and urologists/gynecologists, in the multidisciplinary approach to treating patients with SD and depression.
METHODS: Our review focuses on articles published within the last 10 years on SD and depression in adults, with an emphasis on the relationship of treatments for depression on SD.
SUMMARY: Different classes of antidepressants vary in their ability to cause sexual side effects.
RESULTS: Treatment with selective serotonin reuptake inhibitors (SSRIs) and serotonin/norepinephrine reuptake inhibitors (SNRIs) is associated with SD. Use of other antidepressants, such as bupropion, mirtazapine, nefazodone, and vilazodone, have been associated with less SD compared with SSRIs; furthermore, some of the mentioned antidepressants have been used in the treatment of SD induced by SSRIs and SNRIs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24685972     DOI: 10.3810/pgm.2014.03.2744

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  13 in total

Review 1.  Selective serotonin reuptake inhibitors for fibromyalgia syndrome.

Authors:  Brian Walitt; Gerard Urrútia; María Betina Nishishinya; Sarah E Cantrell; Winfried Häuser
Journal:  Cochrane Database Syst Rev       Date:  2015-06-05

2.  Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.

Authors:  Ramakrishna Nirogi; Renny Abraham; Pradeep Jayarajan; Venkatesh Goura; Rajesh Kallepalli; Rajesh Babu Medapati; Jayaprakash Tadiparthi; Vinod Kumar Goyal; Santosh Kumar Pandey; Ramkumar Subramanian; Surendra Petlu; Jagadeesh Babu Thentu; Veera Raghava Chowdary Palacharla; Shankar Reddy Gagginapally; Abdul Rasheed Mohammed; Venkat Jasti
Journal:  Psychopharmacology (Berl)       Date:  2022-03-17       Impact factor: 4.530

3.  Acute caffeine reverses the disruptive effects of chronic fluoxetine on the sexual behavior of female and male rats.

Authors:  Brunella V González Cautela; Gonzalo R Quintana; Jessica Akerman; James G Pfaus
Journal:  Psychopharmacology (Berl)       Date:  2020-11-26       Impact factor: 4.530

4.  Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.

Authors:  Anita H Clayton; Carl Gommoll; Dalei Chen; Rene Nunez; Maju Mathews
Journal:  Int Clin Psychopharmacol       Date:  2015-07       Impact factor: 1.659

5.  The whole versus the sum of some of the parts: toward resolving the apparent controversy of clitoral versus vaginal orgasms.

Authors:  James G Pfaus; Gonzalo R Quintana; Conall Mac Cionnaith; Mayte Parada
Journal:  Socioaffect Neurosci Psychol       Date:  2016-10-25

6.  Effect of Depression and Antidepressants on Sexual Dysfunction in Men with Diabetes: A National Population-Based Cohort Study.

Authors:  Yao-Hsu Yang; Vincent Chin-Hung Chen; Pei-Lun Chung; Chien-Wei Huang; Min-Jing Lee; Ko-Jung Chen; Mong-Liang Lu; Jun-Cheng Weng
Journal:  Neuropsychiatr Dis Treat       Date:  2020-04-30       Impact factor: 2.570

7.  Disorders related to sexuality and gender identity in the ICD-11: revising the ICD-10 classification based on current scientific evidence, best clinical practices, and human rights considerations.

Authors:  Geoffrey M Reed; Jack Drescher; Richard B Krueger; Elham Atalla; Susan D Cochran; Michael B First; Peggy T Cohen-Kettenis; Iván Arango-de Montis; Sharon J Parish; Sara Cottler; Peer Briken; Shekhar Saxena
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

8.  Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies.

Authors:  Anita H Clayton; Suresh Durgam; Xiongwen Tang; Changzheng Chen; Adam Ruth; Carl Gommoll
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-21       Impact factor: 2.570

9.  Comparing the Efficacy of Bupropion and Amantadine on Sexual Dysfunction Induced by a Selective Serotonin Reuptake Inhibitor.

Authors:  Alireza Zahiroddin; Farhad Faridhosseini; Azar Zamani; Najmeh Shahini
Journal:  Iran Red Crescent Med J       Date:  2015-12-05       Impact factor: 0.611

Review 10.  Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.

Authors:  Oloruntoba J Oluboka; Martin A Katzman; Jeffrey Habert; Diane McIntosh; Glenda M MacQueen; Roumen V Milev; Roger S McIntyre; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.